A multicenter, open-label study to determine the safety and efficacy of single-agent CC-5013 [lenalidomide] in subjects with relapsed or refractory multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 Sep 2009 Actual end date changed from Dec 2005 to Mar 2007 as reported by ClinicalTrials.gov.
- 08 Jun 2009 An analysis of this trial is to be presented at the 14th Congress of the European Hematology Association (EHA), according to a Celgene media release.
- 06 Jun 2008 Status changed to completed as reported in an abstract presented at ASCO 2008.